Idorsia Ltd (OTCMKTS:IDRSF) Stock Short Interest Falls 35.0%

Idorsia Ltd (OTCMKTS:IDRSF) saw a significant drop in short interest in October. As of October 15th, there was short interest totaling 6,184,041 shares, a drop of 35.0% from the September 30th total of 9,515,618 shares. Based on an average trading volume of 2,261 shares, the short-interest ratio is presently 2,735.1 days.

Idorsia Stock Performance

Shares of OTCMKTS IDRSF opened at $4.95 on Monday. Idorsia has a 12 month low of $3.50 and a 12 month high of $8.19. The company has a 50 day simple moving average of $5.85 and a two-hundred day simple moving average of $5.67.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating on shares of Idorsia in a research report on Monday, September 14th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Idorsia in a research report on Monday, August 3rd. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, Idorsia presently has a consensus rating of “Moderate Buy”.

Idorsia Company Profile

Idorsia Ltd. is a Swiss biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. Its research activities span areas including cardiovascular disease, central nervous system disorders, immunology and rare diseases. The company operates from its headquarters in Allschwil, Switzerland, and serves international pharmaceutical markets through its own commercial operations and collaboration arrangements.

Idorsia’s commercial portfolio includes QUVIVIQ (daridorexant), an orexin receptor antagonist used to treat insomnia in eligible adults, and PIVLAZ (clazosentan), a therapy intended to reduce the risk of cerebral vasospasm and related complications following aneurysmal subarachnoid hemorrhage.